1. N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials.
- Author
-
Stenstrom DA, Muldoon LL, Armijo-Medina H, Watnick S, Doolittle ND, Kaufman JA, Peterson DR, Bubalo J, and Neuwelt EA
- Subjects
- Acetylcysteine pharmacology, Acetylcysteine toxicity, Clinical Trials, Phase III as Topic, Humans, Acetylcysteine therapeutic use, Contrast Media adverse effects, Kidney Diseases chemically induced, Kidney Diseases prevention & control
- Abstract
To date there has been no general consensus regarding the effectiveness of N-acetylcysteine as a protective therapy against contrast medium-induced nephropathy. Several phase III clinical trials have been conducted without a proper understanding of N-acetylcysteine pharmacology, particularly with regard to first-pass hepatic metabolism. A review was conducted of the literature concerning contrast medium-induced nephropathy and new studies of human N-acetylcysteine pharmacology were performed. After an analysis was performed, it was concluded that further phase I and phase II trials are needed. The efficacy of N-acetylcysteine in the prevention of contrast medium-induced nephropathy may be demonstrated with the use of higher doses than used in earlier studies, in combination with parenteral administration.
- Published
- 2008
- Full Text
- View/download PDF